Literature DB >> 15901282

Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth.

Elizabeth Vincan1, Phillip K Darcy, Mark J Smyth, Erik W Thompson, Robert J S Thomas, Wayne A Phillips, Robert G Ramsay.   

Abstract

Frizzled (FZD) receptors have a conserved N-terminal extracellular cysteine-rich domain that interacts with Wnts and co-expression of the receptor ectodomain can antagonize FZD-mediated signalling. Using the ectodomain as an antagonist we have modulated endogenous FZD7 signalling in the moderately differentiated colon adenocarcinoma cell line, SK-CO-1. Unlike the parental cell line, which grows as tightly associated adherent cell clusters, the FZD7 ectodomain expressing cells display a spread out morphology and grow as a monolayer in tissue culture. This transition in morphology was associated with decreased levels of plasma membrane-associated E-cadherin and beta-catenin, localized increased levels of vimentin and redistribution of alpha6 integrin to cellular processes in the FZD7 ectodomain expressing cells. The morphological and phenotype changes induced by FZD7 ectodomain expression in SK-CO-1 cells is thus consistent with the cells undergoing an epithelial-to-mesenchymal-like transition. Furthermore, initiation of tumor formation in a xenograft tumor growth assay was attenuated in the FZD7 ectodomain expressing cells. Our results indicate a pivotal role for endogenous FZD7 in morphology transitions that are associated with colon tumor initiation and progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901282     DOI: 10.1111/j.1432-0436.2005.00015.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  23 in total

Review 1.  Targeting Wnt pathways in disease.

Authors:  Zachary F Zimmerman; Randall T Moon; Andy J Chien
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

2.  Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer.

Authors:  M Li; Z W Zhao; Y Zhang; Y Xin
Journal:  Dig Dis Sci       Date:  2010-08-05       Impact factor: 3.199

Review 3.  Frizzled7 as an emerging target for cancer therapy.

Authors:  Taj D King; Wei Zhang; Mark J Suto; Yonghe Li
Journal:  Cell Signal       Date:  2011-12-13       Impact factor: 4.315

4.  Shiga-like toxin I exerts specific and potent anti-tumour efficacy against gastric cancer cell proliferation when driven by tumour-preferential Frizzled-7 promoter.

Authors:  Hongpan Xu; Lijun Peng; Mengjiao Shen; Yanyan Xia; Zhiyang Li; Nongyue He
Journal:  Cell Prolif       Date:  2019-04-06       Impact factor: 6.831

Review 5.  WNTS and WNT receptors as therapeutic tools and targets in human disease processes.

Authors:  Andy J Chien; Randall T Moon
Journal:  Front Biosci       Date:  2007-01-01

Review 6.  The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression.

Authors:  Elizabeth Vincan; Nick Barker
Journal:  Clin Exp Metastasis       Date:  2008-03-19       Impact factor: 5.150

7.  Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis.

Authors:  E Louie; X F Chen; A Coomes; K Ji; S Tsirka; E I Chen
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

8.  Frizzled-7 as a potential therapeutic target in colorectal cancer.

Authors:  Koji Ueno; Mikako Hiura; Yutaka Suehiro; Shoichi Hazama; Hiroshi Hirata; Masaaki Oka; Kohzoh Imai; Rajvir Dahiya; Yuji Hinoda
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

Review 9.  Frizzled homolog proteins, microRNAs and Wnt signaling in cancer.

Authors:  Koji Ueno; Hiroshi Hirata; Yuji Hinoda; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2012-08-30       Impact factor: 7.396

10.  The p53 transcriptional target gene wnt7b contributes to NGF-inducible neurite outgrowth in neuronal PC12 cells.

Authors:  Christopher Brynczka; B Alex Merrick
Journal:  Differentiation       Date:  2008-01-03       Impact factor: 3.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.